(VIANEWS) – Shares of Inovio Pharmaceuticals (NASDAQ: INO) fell by a staggering 20.75% in 10 sessions from $2.41 at 2022-11-14, to $1.91 at 14:10 EST on Tuesday, after five successive sessions in a row of losses. NASDAQ is sliding 0.55% to $10,988.54, after two sequential sessions in a row of losses.
Inovio Pharmaceuticals’s last close was $1.90, 75.55% below its 52-week high of $7.77.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology firm that focuses on developing, commercializing, and marketing DNA medicines. These drugs are used to protect and treat people against diseases such as cancer, human papillomavirus, and other infectious diseases. The DNA medicines platform utilizes precisely-designed SynCon to identify and optimize DNA sequences of target antigens. CELLECTRA smart device technology facilitates the delivery of DNA plasmids. It plans clinical trials of DNA medicines to treat HPV-associated diseases, including anal and cervical dysplasia, vulvar and cervical precancers; HPV associated cancers such as cervical and anal papillomatosis, head and neck cancer, vaginal cancer, HIV, Ebola, Middle East Respiratory syndrome (MERS), and Lassa fever. ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, (DARPA), Defense Advanced Research Projects Agency, Defense Advanced Research Projects Agency, Department of Defense (DoD), HIV Vaccines Trial Network, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Regeneron Pharmaceuticals, Thero Fisher Scientific, Thermo Fisher Military Institute of Research, The Wistar Institute of Research, University of Research, Walter Reed Army Institute of Research, University of Research, University of Research, University of Research, University of Research, University of Research, Thero Fisher Scientific, Thero Fisher Research, Thermo Fisher to support thero Fisher Research, Thermo Fisher s, Thermo Fisher Research, Thermo Fisher & Thermo To support the investigational DNA vaccine, INO-4800 for COVID-19, Richter-Helm BioLogics GmbH & Co. KG has been entered into an agreement. The partnership also includes International Vaccine Institute (Seoul National University Hospital) and Regeneron Pharmaceuticals. Plymouth Meeting is the headquarters of this company, which was established in 1979.
Earnings per Share
Inovio Pharmaceuticals’ trailing 12 months profit per share was $-1.073.
For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was negative at -87.99%.
More news about Inovio Pharmaceuticals (INO).